Ironwood Pharmaceuticals Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
4.32 1.89
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
3.89
Max
4.37
Pajamos | -21M 41M |
|---|---|
Pardavimai | 59M 107M |
P/E Sektoriaus vid. | 7.129 68.51 |
Pelnas, tenkantis vienai akcijai | 0.24 |
Pelno marža | 38.282 |
Darbuotojai | 100 |
EBITDA | 66M 75M |
Rinkos kapitalizacija | -28M 728M |
|---|---|
Ankstesnė atidarymo kaina | 2.43 |
Ankstesnė uždarymo kaina | 4.32 |
Naujienos nuotaikos
By Acuity
22%
78%
58 / 340 reitingas Healthcare
Ironwood Pharmaceuticals Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Ironwood Pharmaceuticals Inc Prognozė
Rinkos nuotaikos
By Acuity
58 / 340 reitingas Sveikatos priežiūra
Naujienos nuotaikos
Labai stiprus bulių rinkos įrodymas
Svyravimai
Žemiau vidurkio
Naujienų apimtis (RCV)
Aukščiau vidurkio
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
